Literature DB >> 22134974

Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.

Absalon D Gutierrez1, Ashok Balasubramanyam.   

Abstract

HIV-infected patients on highly active antiretroviral therapy (HAART) have increased prevalence of a number of chronic metabolic disorders of multifactorial but unclear etiology. These include disorders of lipid metabolism with or without lipodystrophy, insulin resistance, and an increased prevalence of impaired glucose tolerance, diabetes mellitus, and cardiometabolic syndrome. While much attention has been focused on the lipid and cardiovascular disorders, few investigations have attempted to characterize the prevalence, incidence, etiology, mechanisms, and management of glycemic disorders in HIV patients. In this review, we have focused specifically on a comprehensive assessment of dysglycemia in the context of HIV infection and HAART.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22134974      PMCID: PMC3417129          DOI: 10.1007/s12020-011-9565-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  127 in total

1.  Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.

Authors:  Jennifer H Lee; Jean L Chan; Epaminondas Sourlas; Vassilios Raptopoulos; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2006-04-24       Impact factor: 5.958

Review 2.  Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction.

Authors:  C M Shikuma; L J Day; M Gerschenson
Journal:  Curr Drug Targets Infect Disord       Date:  2005-09

Review 3.  Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

Authors:  Morris Schambelan; Constance A Benson; Andrew Carr; Judith S Currier; Michael P Dubé; John G Gerber; Steven K Grinspoon; Carl Grunfeld; Donald P Kotler; Kathleen Mulligan; William G Powderly; Michael S Saag
Journal:  J Acquir Immune Defic Syndr       Date:  2002-11-01       Impact factor: 3.731

4.  Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation.

Authors:  Jean-Marc Schwarz; Kathleen Mulligan; Jeongae Lee; Joan C Lo; Michael Wen; Mustafa A Noor; Carl Grunfeld; Morris Schambelan
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

5.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

Authors:  C Grunfeld; M Pang; W Doerrler; J K Shigenaga; P Jensen; K R Feingold
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

6.  Growth hormone secretion among HIV infected patients: effects of gender, race and fat distribution.

Authors:  Polyxeni Koutkia; Kristina Eaton; Sung Min You; Jeff Breu; Steven Grinspoon
Journal:  AIDS       Date:  2006-04-04       Impact factor: 4.177

7.  Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome.

Authors:  Carmine Gazzaruso; Raffaele Bruno; Adriana Garzaniti; Stefano Giordanetti; Pietro Fratino; Paolo Sacchi; Gaetano Filice
Journal:  J Hypertens       Date:  2003-07       Impact factor: 4.844

8.  Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy.

Authors:  Shashi Shrivastav; Tomoshige Kino; Tshaka Cunningham; Takamasa Ichijo; Ulrich Schubert; Peter Heinklein; George P Chrousos; Jeffrey B Kopp
Journal:  Mol Endocrinol       Date:  2007-10-11

9.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Authors:  Signe Westring Worm; Caroline Sabin; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Eric Fontas; Ian Weller; Andrew Phillips; Jens Lundgren
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

10.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.

Authors:  T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

View more
  33 in total

1.  An increased risk for fractures: another cause of frailty in HIV-infected subjects.

Authors:  Carmine Gazzaruso
Journal:  Endocrine       Date:  2012-06       Impact factor: 3.633

2.  Pioglitazone therapy for HIV/HAART-associated lipodystrophy syndrome could increase subcutaneous fat mass in non-lipoatrophic but not in lipoatrophic regions.

Authors:  Sadanori Okada; Mitsuru Konishi; Hitoshi Ishii
Journal:  BMJ Case Rep       Date:  2016-02-25

3.  The New Orleans Alcohol Use in HIV Study: Launching a Translational Investigation of the Interaction of Alcohol Use with Biological and Socioenvironmental Risk Factors for Multimorbidity in People Living with HIV.

Authors:  David A Welsh; Tekeda Ferguson; Katherine P Theall; Liz Simon; Angela Amedee; Robert W Siggins; Steve Nelson; Meghan Brashear; Donald Mercante; Patricia E Molina
Journal:  Alcohol Clin Exp Res       Date:  2019-03-10       Impact factor: 3.455

4.  Designer adiponectin receptor agonist stabilizes metabolic function and prevents brain injury caused by HIV protease inhibitors.

Authors:  Jennifer K Pepping; Laszlo Otvos; Eva Surmacz; Sunita Gupta; Jeffrey N Keller; Annadora J Bruce-Keller
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-23       Impact factor: 4.147

Review 5.  Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

Authors:  Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski
Journal:  World J Virol       Date:  2015-05-12

6.  High prevalence of radiological vertebral fractures in HIV-infected males.

Authors:  Carlo Torti; Gherardo Mazziotti; Pier Antonio Soldini; Emanuele Focà; Roberto Maroldi; Daria Gotti; Giampiero Carosi; Andrea Giustina
Journal:  Endocrine       Date:  2011-12-25       Impact factor: 3.633

Review 7.  Osteoporosis in Human Immunodeficiency Virus Patients - An Emerging Clinical Concern.

Authors:  Filippo Maffezzoni; Teresa Porcelli; Ioannis Karamouzis; Eugenia Quiros-Roldan; Francesco Castelli; Gherardo Mazziotti; Andrea Giustina
Journal:  Eur Endocrinol       Date:  2014-02-28

8.  Association of Dyslipidemia and Glucose Abnormalities With Antiretroviral Treatment in a Cohort of HIV-Infected Latin American Children.

Authors:  Machline P Paganella; Rachel A Cohen; Donald R Harris; Ricardo de Souza Kuchenbecker; Rosa D Sperhacke; Sergio K Kato; Carmem L Oliveira da Silva; Fernanda T Sturzbecher; Ricardo H S Oliveira; Noris Pavía-Ruz; Rohan Hazra
Journal:  J Acquir Immune Defic Syndr       Date:  2017-01-01       Impact factor: 3.731

Review 9.  Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS.

Authors:  Ovidiu Galescu; Amrit Bhangoo; Svetlana Ten
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

10.  [HIV infection : chronic disease with comorbidities].

Authors:  J R Bogner
Journal:  Internist (Berl)       Date:  2012-10       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.